A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
University Hospital, Lille
PrECOG, LLC.
Lumicell, Inc.
Fundación GECP
H. Lee Moffitt Cancer Center and Research Institute
Ipsen
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
PharmaMar
Azienda USL Reggio Emilia - IRCCS
Columbia University
University Hospital Southampton NHS Foundation Trust
Memorial Sloan Kettering Cancer Center
University of Southampton
Gruppo Oncologico Italiano di Ricerca Clinica
Ipsen
Radboud University Medical Center
Canadian Cancer Trials Group
Symphogen A/S
Ain Shams University
University of Chicago
Bristol-Myers Squibb
Amphera BV
University of Chicago
Massachusetts General Hospital
University of Florida
University of Hull
Candel Therapeutics, Inc.
PrECOG, LLC.
Eastern Cooperative Oncology Group
Memorial Sloan Kettering Cancer Center
Xencor, Inc.
M.D. Anderson Cancer Center
Baylor College of Medicine
Incyte Corporation
Calithera Biosciences, Inc
Augusta University
Radboud University Medical Center
Stony Brook University
AbbVie
AbbVie
Eli Lilly and Company
Shionogi Inc.
Dana-Farber Cancer Institute
Incyte Corporation
Wales Cancer Trials Unit
Swiss Cancer Institute